Bernhard Schmierer

Head of CRISPR Functional Genomic

Karolinska Institutet

Sweden

Research Interests

Explore related searches

Professors in Sweden Professors in Immunology Immunology professors in Sweden

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Bernhard Schmierer is the Head of CRISPR Functional Genomic at Karolinska Institutet in Sweden. His research focuses on CRISPR technology and its applications in cancer genomics, including the identification of DNA damage response pathways and enhancing our understanding of cancer cell plasticity. His recent articles explore various aspects of CRISPR-related methodologies and their implications in drug target discovery and cancer treatment.

Articles (7)

Year:

2025

Year:

2024

Year:

2024

Year:

2023

Year:

2022

Year:

2021

Year:

2020

Collaborators (6)

Fredrik Wermeling

Associate Professor

Karolinska Institutet

SWEDEN

View details

Alfonso Martín-Bernabé

Karolinska Institutet

SWEDEN

View details

Eivind Valen

Professor at University of Oslo

University of Oslo

NORWAY

View details

Peter Krijger

Hubrecht Institute

NETHERLANDS

View details

Pádraig D'Arcy

Lecturer, Researcher

Linköping University

SWEDEN

View details

Andrea C. del Valle

Karolinska Institutet

SWEDEN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Bernhard Schmierer

Research Interests

Explore related searches

Contact this professor

About

Articles (7)

Identification of a SNAI1 enhancer RNA that drives cancer cell plasticity

CRISPR-Cas9 Knockout Screens Identify DNA Damage Response Pathways and <i>BTK</i> as Essential for Cisplatin Response in Diffuse Large B-Cell Lymphoma

Radiolabeled 15-mer peptide internalization is mediated by megalin (LRP2 receptor) in a CRISPR/Cas9-based LRP2 knockout human kidney cell model.

An idiosyncratic zonated stroma encapsulates desmoplastic liver metastases and originates from injured liver.

Comprehensive Target Screening and Cellular Profiling of the Cancer-Active Compound b-AP15 Indicate Abrogation of Protein Homeostasis and Organelle Dysfunction as the Primary Mechanism of Action.

Rapid genome editing by CRISPR-Cas9-POLD3 fusion.

Designing custom CRISPR libraries for hypothesis-driven drug target discovery

Collaborators (6)

Fredrik Wermeling

Alfonso Martín-Bernabé

Eivind Valen

Peter Krijger

Pádraig D'Arcy

Andrea C. del Valle

Make your next move.